Search Result

Results for "

lipid lowering

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ACSL Family (1) Acyltransferase (1) Akt (5) Aldose Reductase (2) AMPK (3) Amylin Receptor (1) Antibiotic (2) AP-1 (3) Apical Sodium-Dependent Bile Acid Transporter (1) Apolipoprotein (1) Apoptosis (20) ATP Citrate Lyase (1) Autophagy (16) Bacterial (8) Bcl-2 Family (10) Biochemical Assay Reagents (4) c-Myc (2) Calcium Channel (1) Carnitine Palmitoyltransferase (CPT) (1) Caspase (3) CGRP Receptor (1) COX (1) Cytochrome P450 (5) DAGL (1) Drug Derivative (3) Drug Isomer (1) Drug Metabolite (6) Endogenous Metabolite (17) ERK (1) Estrogen Receptor/ERR (3) Farnesyl Transferase (3) Fatty Acid Synthase (FASN) (2) Ferroptosis (4) FGFR (1) Free Fatty Acid Receptor (1) Fungal (1) FXR (2) G protein-coupled Bile Acid Receptor 1 (1) GCGR (2) GLP Receptor (12) GLUT (1) Glutathione Peroxidase (3) Glycosidase (1) GSK-3 (2) HCV (3) HMG-CoA Reductase (HMGCR) (7) Hydroxycarboxylic Acid Receptor (HCAR) (1) Influenza Virus (2) Insulin Receptor (8) Interleukin Related (7) Isotope-Labeled Compounds (11) JAK (2) JNK (1) Keap1-Nrf2 (3) LDLR (10) Liposome (4) LXR (1) MAGL (1) MDM-2/p53 (2) Microsomal Triglyceride Transfer Protein (MTP) (1) Mitochondrial Metabolism (3) MMP (2) mTOR (1) NADPH Oxidase (1) Neurokinin Receptor (1) NF-κB (8) NO Synthase (3) NOD-like Receptor (NLR) (1) Nuclear Hormone Receptor 4A/NR4A (1) p38 MAPK (8) PCSK9 (6) PGE synthase (1) Phosphatase (1) PI3K (3) PKC (1) Platelet-activating Factor Receptor (PAFR) (1) Potassium Channel (2) PPAR (18) Prostaglandin Receptor (1) PROTAC Linkers (1) Pyroptosis (1) Reactive Oxygen Species (ROS) (6) Reference Standards (20) SARS-CoV (2) Ser/Thr Protease (1) Sirtuin (1) SOD (7) TGF-β Receptor (1) Thyroid Hormone Receptor (1) TNF Receptor (6) UGT (1) α-synuclein (8) β-catenin (2) β-glucuronidase (1)
By Research Areas:	Cancer (41) Cardiovascular Disease (39) Endocrinology (7) Infection (17) Inflammation/Immunology (28) Metabolic Disease (94) Neurological Disease (19)
Oligonucleotides:	Phospholipids (1) Cationic Lipids (2) Polymers (1)

139

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W001171

3-Hydroxyanthranilic acid 1 Publications Verification	Endogenous Metabolite	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
3-Hydroxyanthranilic acid is a tryptophan metabolite in the kynurenine pathway.3-hydroxyanthranilic acid has anti-inflammatory, neuroprotective, and lipid-lowering effects. 3-hydroxyanthranilic acid can be used for researches of cardiovascular diseases, tumors, and metabolic diseases .

HY-N6653

Lentinan Maximum Cited Publications 8 Publications Verification	JAK Keap1-Nrf2 Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
Lentinan is an orally active biocompatible multifunctional polysaccharide with biological activities such as anti-inflammatory, antioxidant, immune regulation, anti-tumor, hypoglycemic, and lipid-lowering ^[1][4].

HY-B0258

Gemfibrozil 5+ Cited Publications CI-719	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-W012241

Dodecanedioic acid	Endogenous Metabolite PROTAC Linkers	Metabolic Disease
Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-B1028

Pantethine 5 Publications Verification D-Pantethine; LBF disulfide	Endogenous Metabolite SARS-CoV	Cardiovascular Disease Neurological Disease Inflammation/Immunology Endocrinology Cancer
Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .

HY-17408

Mevastatin 5+ Cited Publications Compactin; ML236B	HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .

HY-N0458

Pedunculoside 3 Publications Verification	Fatty Acid Synthase (FASN)	Metabolic Disease
Pedunculoside exerts lipid-lowering effects partly through the regulation of?lipogenesis?and?fatty acid β-oxidation .

HY-W006405

Isoflavone	Estrogen Receptor/ERR	Cardiovascular Disease Cancer
Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases .

HY-16643

Linerixibat 10+ Cited Publications GSK2330672	Apical Sodium-Dependent Bile Acid Transporter	Infection Metabolic Disease Inflammation/Immunology
Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC₅₀ of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment .

HY-109523

Cerivastatin sodium 2 Publications Verification	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-101701

Hepronicate Megrin	Drug Derivative	Cardiovascular Disease
Hepronicate, a nicotinic acid derivative, is a peripheral vasodilator with blood lipid lowering action. Hepronicate works by improving peripheral circulatory disturbances .

HY-14925

Lapaquistat 2 Publications Verification T-91485	Endogenous Metabolite Drug Metabolite	Metabolic Disease
Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .

HY-107582

JW480	Ser/Thr Protease Calcium Channel PKC	Cancer
JW480 is a selective KIAA1363/AADACL1 inhibitor with oral activity, featuring IC₅₀ values of 12 nM against human KIAA1363, 20 nM against mouse KIAA1363. JW480 blocks lipid deacetylase activity to restrain HAG metabolism and lowers retinyl ester hydrolase function in hepatic stellate cells. JW480 reduces MAGE lipid levels and inhibits migration, invasion, survival and tumor growth of prostate cancer cells. JW480 lowers PKCδ phosphorylation, facilitates HAGP accumulation, diminishes platelet aggregation, dense granule secretion and Ca ²⁺ flux, delays arterial thrombosis and prolongs tail bleeding time in rats. JW480 can be used for the study of prostate cancer and thrombosis .

HY-100313A

YM-53601 5 Publications Verification	Farnesyl Transferase HCV	Infection Metabolic Disease
YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .

HY-B1189

Meglutol Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid	HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .

HY-129459

α-Tocotrienol	Endogenous Metabolite	Cardiovascular Disease Neurological Disease
α-Tocotrienol is an isoform of vitamin E and found in vegetables, fruits, seeds, nuts, grains, and oils. Vitamin E plays a role as an antioxidant, in lowering cholesterol and other lipids, as a neuroprotective and anticancer agent, and in cardiovascular disease protection.

HY-122778

δ-Tocotrienol 1 Publications Verification	NF-κB AP-1 Caspase Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
δ-Tocotrienol is a Vitamin E in vegetables, fruits, seeds, nuts, grains and oils. Vitamin E has become well known for its role as an antioxidant, in lowering cholesterol and other lipids, as a neuroprotective and anticancer agent, and in cardiovascular disease protection.

HY-N0224

Epigoitrin 1 Publications Verification	Influenza Virus	Infection Metabolic Disease Cancer
Epigoitrin is a natural alkaloid that provides protection against influenza infection by reducing the host’s susceptibility to influenza virus under stress. Epigoitrin exerts antiviral activity against influenza A1 virus FM1 via inhibiting virus attachment and multiplication in vitro. Epigoitrin also has lipid-lowering effects .

HY-B1415

Clofibric acid Chlorofibrinic acid	PPAR Bacterial SOD	Infection Metabolic Disease Cancer
Clofibric acid (Chlorofibrinic acid) is an orally active PPARα agonist. Clofibric acid inhibits the fimbriation of *Escherichia coli. Clofibric acid increases SOD* activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research .

HY-109567

Gemcabene PD-72953	LDLR	Metabolic Disease Inflammation/Immunology
Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .

HY-N9811

Hydroxytyrosol 4-O-glucoside	Drug Derivative	Infection Metabolic Disease
Hydroxytyrosol 4-O-glucoside is a phenolic compound found in olive pulp, vegetation water, and pomace of olive oil processing. Hydroxytyrosol 4-O-glucoside can be used in research on antibacterial, hypoglycemic, lipid-lowering, and cholesterol-lowering effects .

HY-119546

Pinolenic acid PNLA	Free Fatty Acid Receptor	Inflammation/Immunology
Pinolenic acid (PNLA) is a polyunsaturated fatty acid that can be isolated from Pinus orientalis and Pinus pinaster seed oil. Pinolenic acid has anti-inflammatory and lipid-lowering activities .

HY-N0309

Soyasaponin Ba 1 Publications Verification	Aldose Reductase Akt GSK-3 β-catenin Reactive Oxygen Species (ROS) Mitochondrial Metabolism Apoptosis c-Myc	Metabolic Disease
Soyasaponin Ba is a soyasaponin that can be isolated from Phaseolus vulgaris, acts as an aldose reductase inhibitor (ARI). Soyasaponin Ba activates Akt/GSK3β/β-catenin signaling pathway, reduces lipid accumulation, lowers ROS generation, improves mitochondrial membrane potential, ATP levels, and morphology, and inhibits apoptosis. Soyasaponin Ba can be used for the research of lipid accumulation and secondary diabetic complications .

HY-130345

PAF (C18)	Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
C18-PAF, octadecane PAF, is the ligand of platelet-activating factor and PAF G protein-coupled receptor (PAFR). C18-PAF has renovasodilator properties and antihypertensive lipid properties. C18-PAF increases renal blood flow and causes dose-dependent systemic hypotension .

HY-116175

BIBB 515	LDLR	Metabolic Disease
BIBB 515 is a potent, selective and orally active 2,3-oxidosqualene cyclase (OSC) inhibitor with ED₅₀ values of 0.2-0.5 mg/kg and 0.36-33.3 mg/kg in rats and mice (1-5 hours), respectively. BIBB 515 exerts lipid-lowering effect mainly by inhibiting the production of low-density lipoprotein (LDL) .

HY-162562

E28362	PCSK9	Metabolic Disease Inflammation/Immunology
E28362 is an orally active lipid-lowering agent and a selective PCSK9 antagonist. E28362 blocks the interaction between PCSK9 and LDLR, and induces PCSK9 degradation via the ubiquitin-proteasome pathway. E28362 significantly increases the levels of cell surface and total LDLR proteins, enhances low-density lipoprotein uptake, thereby effectively reducing plasma lipids, hepatic cholesterol and triglyceride levels. E28362 shows no obvious cytotoxicity at high concentrations, and significantly attenuates atherosclerotic lesions in animal models. E28362 is an important molecule in research of hyperlipidemia and atherosclerosis .

HY-16421

Ragaglitazar (-)-DRF 2725; NNC 61-0029	PPAR	Metabolic Disease
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

HY-134769

OPC-163493	Mitochondrial Metabolism Reactive Oxygen Species (ROS)	Cardiovascular Disease Metabolic Disease
OPC-163493 is an orally active and liver-targeted mitochondrial uncoupling agent. OPC-163493 reduces the production of mitochondrial Δψ and ROS. OPC-163493 has anti-diabetic and lipid-lowering effects. In addition, OPC-163493 has a protective effect on cardiovascular disease .

HY-115938

BEC2	Carnitine Palmitoyltransferase (CPT) Others	Metabolic Disease Cancer
BEC2 is an ester derivative of Baicalin, with good lipid-lowering activity. BEC2 can direct activate the carnitine palmitoyltransferase 1A (CPT1A) .

HY-100976

LUF6283	Hydroxycarboxylic Acid Receptor (HCAR)	Metabolic Disease
LUF6283 is a potent and orally active HCA(2) partial agonist, with a K_i of 0.55 µM. LUF6283 can achieve the beneficial lipid lowering effect of niacin without producing the unwanted cutaneous flushing side effect .

HY-129459R

α-Tocotrienol (Standard)	Reference Standards Endogenous Metabolite	Cardiovascular Disease Neurological Disease
α-Tocotrienol (Standard) is the analytical standard of α-Tocotrienol. This product is intended for research and analytical applications. α-Tocotrienol is an isoform of vitamin E and found in vegetables, fruits, seeds, nuts, grains, and oils. Vitamin E plays a role as an antioxidant, in lowering cholesterol and other lipids, as a neuroprotective and anticancer agent, and in cardiovascular disease protection.

HY-P99696

Lerodalcibep LIB003	PCSK9	Cardiovascular Disease Metabolic Disease
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .

HY-175725

NR4A1 agonist 1	Nuclear Hormone Receptor 4A/NR4A	Metabolic Disease
NR4A1 agonist 1 is a NR4A1 agonist with a K_i value of 2.96 μM. NR4A1 agonist 1 exhibits lipid-lowering activity in 3T3-L1 adipocytes, with an EC₅₀ of 0.13 μM, significantly decreasing triglyceride (TG) accumulation and lipid droplet accumulation. NR4A1 agonist 1 can be used for the study of obesity .

HY-P3388

Utreglutide	GLP Receptor	Cardiovascular Disease Metabolic Disease
Utreglutide is an effective glucagon-like peptide 1 (GLP-1) receptor agonist. Utreglutide can lower blood pressure, blood lipids and body weight, and improve cardiovascular metabolism. Utreglutide can be used for research on type 2 diabetes or non-type 2 diabetes obesity .

HY-113820

AZD4619	PPAR	Metabolic Disease
AZD4619 is an orally active, selective peroxisome proliferator-activated receptor α (PPARα) agonist. AZD4619 increases alanine aminotransferase 1 (ALT1) protein expression in a dose-dependent manner in human, but not in rat primary hepatocytes. AZD4619 is a lipid-lowering drug .

HY-B0258S

Gemfibrozil-d6 CI-719-d₆	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-129458

Cerivastatin	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-B0258R

Gemfibrozil (Standard) 5+ Cited Publications CI-719 (Standard)	Reference Standards PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil (Standard) is the analytical standard of Gemfibrozil. This product is intended for research and analytical applications. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-W144096

Methyl 2,4,6-trihydroxybenzoate	Drug Metabolite	Metabolic Disease Cancer
Methyl 2,4,6-trihydroxybenzoate is a metabolite of 2,4,6-trihydroxybenzoate and exhibits properties as an antioxidant, lipid lowering and anticancer activities .

HY-P3491

Pegloxenatide Polyethylene glycol loxenatide; PEX 168	GCGR PI3K Akt Reactive Oxygen Species (ROS) Autophagy Interleukin Related Sirtuin AMPK Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Pegloxenatide (Polyethylene glycol loxenatide) is a long-acting glucagon-like peptide-1 receptor (GLP-1RA) agonist. Pegloxenatide has various activities such as lowering blood glucose, lowering blood lipids, improving body weight, anti-inflammation, promoting wound healing, protecting the liver, and protecting the heart. Pegloxenatide can be used in the research of type 2 diabetes and its multiple complications .

HY-148626

CVI-LM001	PCSK9	Metabolic Disease
CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .

HY-159595

PCSK9-IN-29	LDLR PCSK9	Metabolic Disease Inflammation/Immunology
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .

HY-W012241S1

Dodecanedioic acid-d4	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Dodecanedioic acid-d₄ is the deuterium labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-W012241R

Dodecanedioic acid (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
Dodecanedioic acid (Standard) is the analytical standard of Dodecanedioic acid (HY-W012241). This product is intended for research and analytical applications. Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-100313

YM-53601 free base	Farnesyl Transferase HCV	Metabolic Disease
YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .

HY-117167

KB-141	Thyroid Hormone Receptor	Cancer
KB-141 is a potent and selective TRβ agonist. The IC₅₀ values are 23.9 nM and 3.3 nM for binding affinities from displacement of T3 from hTRα1 and hTRβ1, respectively. KB-141 has anti-obesity, anti-diabetic, and lipid-lowering effects?and can be used as an anti-cholesteremic agent in vivo .

HY-115914

Lipid-lowering agent-1	LDLR	Others
Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats .

HY-162703

Lipid-lowering agent-2	AMPK	Metabolic Disease
Lipid-lowering agent-2 (Compound 14d) is an orally active lipid-lowering agent with an EC₅₀ of 0.06 μM. Lipid-lowering agent-2 inhibits the lipid synthesis, activates the AMPK signaling pathway, and exhibits anti-obesity effect. Lipid-lowering agent-2 inhibits food intake, improves the glucose metabolism, and reduces the body weight and adipose tissue in high-fat diet (HFD)-induced obese mice .

HY-W800776

DORI 1,2-Dioleoyl-3-dimethyl-hydroxyethylammonium bromide	Liposome	Others
DORI is a cationic lipid that can deliver plasmid DNA in vitro. DORI has lower cytotoxicity and high transfection efficiency .

HY-U00340

PPAR agonist 1	PPAR	Metabolic Disease
PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.

Cat. No.	Product Name

HY-L253

Fungal-Sourced Compound Library

88 compounds

For thousands of years, natural products have always been an important source for drug discovery. Fungi, due to their unique and diverse secondary metabolic capabilities, have become a valuable resource for natural active molecules. Since the discovery of penicillin, natural products derived from fungi have demonstrated significant application value in areas such as anti-infection, anti-tumor, immune regulation, and metabolic disease research. A large number of clinical drugs, such as antibiotics, immunosuppressants, and lipid-lowering drugs, are derived from fungal metabolites or their structurally optimized derivatives.

MCE fungal-derived compound library contains 88 structurally diverse and bioactive fungal natural products and their derivatives. It can be widely applied in various research fields such as antibacterial, anti-tumor, anti-inflammatory, immune regulation, epigenetics, and cell signaling pathways, providing high-quality tools for natural product drug development and high-throughput screening.

Cat. No.	Product Name	Type

HY-W591424

m-PEG2000-NHS ester

mPEG2000-SC; mPEG2000-Succinimidyl ester

Biochemical Assay Reagents

m-PEG2000-NHS ester (mPEG2000-SC) is a reagent with both cell adhesion inhibition and peptide conjugation functions. The NHS ester group of m-PEG2000-NHS ester forms stable amide bonds with primary amine-containing molecules (e.g., the N-terminus of MMP-2-cleavable octapeptide) to generate mPEG-peptide intermediates for liposome surface modification. When m-PEG2000-NHS ester is immobilized on a cystamine-modified gold surface, it can construct an in vitro model for cell adhesion kinetic studies, and higher PEG density and thicker layers correlate with lower cell adhesion rates. m-PEG2000-NHS ester can synthesize MMP-2-responsive PEGylated lipid conjugates to achieve MMP-triggered dePEGylation in the tumor microenvironment. m-PEG2000-NHS ester can be used in studies related to colon cancer and other conditions .

HY-124187

Pinolenic acid ethyl ester

Ethyl pinolenate

Biochemical Assay Reagents

Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.

HY-131306B

2-Hexadecenoic acid

Gaidic acid

Biochemical Assay Reagents

2-Hexadecenoic acid is a natural unsaturated fatty acid. It is ubiquitously present in various animal and plant tissues, especially adipose tissue and certain vegetable oils, such as macadamia nut oil. 2-Hexadecenoic acid has unique chemical properties that make it an important component of cell membranes and storage lipids, and participates in various metabolic processes such as lipid metabolism and inflammation. It's also been linked to potential health benefits, including improved insulin sensitivity and a lower risk of heart disease.

Cat. No.	Product Name	Target	Research Area

HY-114118

Semaglutide Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118B

Semaglutide acetate Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118A

Semaglutide TFA Maximum Cited Publications 35 Publications Verification	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118CP

Semaglutide (crude)	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P3388

Utreglutide	GLP Receptor	Cardiovascular Disease Metabolic Disease
Utreglutide is an effective glucagon-like peptide 1 (GLP-1) receptor agonist. Utreglutide can lower blood pressure, blood lipids and body weight, and improve cardiovascular metabolism. Utreglutide can be used for research on type 2 diabetes or non-type 2 diabetes obesity .

HY-P3491

Pegloxenatide Polyethylene glycol loxenatide; PEX 168	GCGR PI3K Akt Reactive Oxygen Species (ROS) Autophagy Interleukin Related Sirtuin AMPK Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Pegloxenatide (Polyethylene glycol loxenatide) is a long-acting glucagon-like peptide-1 receptor (GLP-1RA) agonist. Pegloxenatide has various activities such as lowering blood glucose, lowering blood lipids, improving body weight, anti-inflammation, promoting wound healing, protecting the liver, and protecting the heart. Pegloxenatide can be used in the research of type 2 diabetes and its multiple complications .

HY-P10337

OXM-7	GCGR GLP Receptor	Metabolic Disease Endocrinology
OXM-7 is a dual agonist of GLP-1R (EC₅₀=0.024 nM) and GCGR (EC₅₀=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .

HY-P11588

KBP-042	Amylin Receptor CGRP Receptor	Metabolic Disease
KBP-042 is an orally active amylin receptor activator, a calcitonin receptor activator. KBP-042 induces sustained weight loss, reduces adipose tissue mass, lowers hepatic lipid deposition, increases plasma adiponectin, decreases plasma leptin, and reduces plasma glucose-dependent insulinotropic peptide levels. KBP-042 can be used for the research of obesity and insulin resistance .

HY-114118C

Semaglutide sodium	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99696

Lerodalcibep LIB003	PCSK9	Cardiovascular Disease Metabolic Disease
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .

HY-P99773

Ongericimab JS002	PCSK9	Cardiovascular Disease Metabolic Disease
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W001171

3-Hydroxyanthranilic acid 1 Publications Verification	Human Gut Microbiota Metabolites Monophenols Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Phenols Endogenous metabolite Disease Research Fields	Endogenous Metabolite
3-Hydroxyanthranilic acid is a tryptophan metabolite in the kynurenine pathway.3-hydroxyanthranilic acid has anti-inflammatory, neuroprotective, and lipid-lowering effects. 3-hydroxyanthranilic acid can be used for researches of cardiovascular diseases, tumors, and metabolic diseases .

HY-N7075

Inulin 4 Publications Verification	Structural Classification Human Gut Microbiota Metabolites Polysaccharides Classification of Application Fields Metabolic Disease Plants Compositae Endogenous metabolite Disease Research Fields Saccharides Sophora tomentosa L. Source Classification	Endogenous Metabolite
Inulin is an orally active prebiotic targeting the intestinal microbiota, selectively promoting the proliferation and activity of beneficial bacteria such as bifidobacteria and lactic acid bacteria, and playing a role in regulating the intestinal microecology. The functions of Inulin include: Fermentation by probiotics in the colon to produce short-chain fatty acids (such as butyrate and propionate), lowering the intestinal pH and inhibiting the overgrowth of harmful bacteria; Enhancing the intestinal barrier function and reducing endotoxin translocation; Directly scavenging free radicals (such as superoxide free radicals, hydroxyl free radicals) and activating antioxidant enzymes (SOD, CAT) to reduce oxidative stress. Inulin can also be used in the study of intestinal diseases (constipation, IBD), metabolic syndrome (diabetes, obesity) and liver damage by regulating glucose and lipid metabolism (such as reducing triglycerides, improving insulin sensitivity) and immune response (enhancing NK cell activity, inhibiting inflammatory factors)[1][2][3][4].

HY-N6653

Lentinan Maximum Cited Publications 8 Publications Verification	Polysaccharides Agaricaceae Classification of Application Fields Lentinus edodes (Berk. ) Sing Plants Disease Research Fields Saccharides Source Classification Cancer	JAK Keap1-Nrf2 Apoptosis
Lentinan is an orally active biocompatible multifunctional polysaccharide with biological activities such as anti-inflammatory, antioxidant, immune regulation, anti-tumor, hypoglycemic, and lipid-lowering ^[1][4].

HY-W012241

Dodecanedioic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite PROTAC Linkers
Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-B1028

Pantethine 5 Publications Verification D-Pantethine; LBF disulfide	Natural Products Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite SARS-CoV
Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .

HY-17408

Mevastatin 5+ Cited Publications Compactin; ML236B	Infection Cardiovascular Disease Natural Products Microorganisms Neurological Disease Classification of Application Fields Metabolic Disease Disease Research Fields Source Classification	HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic
Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .

HY-W015924

2-Hydroxyisobutyric acid	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].

HY-N0458

Pedunculoside 3 Publications Verification	Aquifoliaceae Triterpenes Classification of Application Fields Terpenoids Parameria laevigata (Juss.) Moldenke Metabolic Disease Plants Disease Research Fields Source Classification	Fatty Acid Synthase (FASN)
Pedunculoside exerts lipid-lowering effects partly through the regulation of?lipogenesis?and?fatty acid β-oxidation .

HY-W006405

Isoflavone	Flavonoids Classification of Application Fields Leguminosae Glycine max (L.) merr Other Diseases Plants Disease Research Fields Isoflavones Source Classification	Estrogen Receptor/ERR
Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases .

HY-14925

Lapaquistat 2 Publications Verification T-91485	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Drug Metabolite
Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .

HY-N0807

Swertiamarin 1 Publications Verification	Monophenols other families Classification of Application Fields Phenols Zanthoxylum chiloperone var. angustifolium Metabolic Disease Plants Disease Research Fields Cancer	MMP NF-κB JAK Keap1-Nrf2
Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the Nrf2/HO-1 pathway. Swertiamarin can attenuate inflammatory mediators by regulating JAK2/STAT3 transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis .

HY-B1189

Meglutol Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite
Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .

HY-129459

α-Tocotrienol	Cardiovascular Disease Monophenols Neurological Disease Classification of Application Fields Phenols Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
α-Tocotrienol is an isoform of vitamin E and found in vegetables, fruits, seeds, nuts, grains, and oils. Vitamin E plays a role as an antioxidant, in lowering cholesterol and other lipids, as a neuroprotective and anticancer agent, and in cardiovascular disease protection.

HY-N0224

Epigoitrin 1 Publications Verification	Alkaloids Classification of Application Fields Other Alkaloids Cruciferae Isatis tinctoria L. Plants Disease Research Fields Source Classification Cancer	Influenza Virus
Epigoitrin is a natural alkaloid that provides protection against influenza infection by reducing the host’s susceptibility to influenza virus under stress. Epigoitrin exerts antiviral activity against influenza A1 virus FM1 via inhibiting virus attachment and multiplication in vitro. Epigoitrin also has lipid-lowering effects .

HY-N3031

Grosvenorine	Infection Flavonols Structural Classification Flavonoids Classification of Application Fields Cucurbitaceae Phenols Polyphenols Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang Plants Disease Research Fields Source Classification	Bacterial Apoptosis Bcl-2 Family MDM-2/p53 Glutathione Peroxidase SOD TNF Receptor Interleukin Related
Grosvenorine is an orally active flavonoid glycoside found in S. grosvenorii. Grosvenorine exhibits antibacterial, antioxidant and antiinflammation activities. Grosvenorine can induce apoptosis and increases anti-apoptotic Bcl-2 protein expression and reduces pro-apoptotic P53 protein expression in gastric tissues. Grosvenorine enhances mucin/glycoprotein secretion, regulates gastric pH, and reduces gastric lesion incidence.Grosvenorine increases glutathione peroxidase, catalase, and SOD levels, reduces lipid peroxidation (MDA), and lowers TNF-α and IL-6 levels. Grosvenorine can be used for the researches of bacterial infection and Gastric ulcer .

HY-N9811

Hydroxytyrosol 4-O-glucoside	Structural Classification Natural Products Plants Source Classification	Drug Derivative
Hydroxytyrosol 4-O-glucoside is a phenolic compound found in olive pulp, vegetation water, and pomace of olive oil processing. Hydroxytyrosol 4-O-glucoside can be used in research on antibacterial, hypoglycemic, lipid-lowering, and cholesterol-lowering effects .

HY-119546

Pinolenic acid PNLA	Pinaceae Ketones, Aldehydes, Acids Pinus koraiensis Siebold et Zuccarini Plants Source Classification	Free Fatty Acid Receptor
Pinolenic acid (PNLA) is a polyunsaturated fatty acid that can be isolated from Pinus orientalis and Pinus pinaster seed oil. Pinolenic acid has anti-inflammatory and lipid-lowering activities .

HY-N0309

Soyasaponin Ba 1 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Leguminosae Glycine max (L.) merr Terpenoids Metabolic Disease Plants Disease Research Fields Source Classification	Aldose Reductase Akt GSK-3 β-catenin Reactive Oxygen Species (ROS) Mitochondrial Metabolism Apoptosis c-Myc
Soyasaponin Ba is a soyasaponin that can be isolated from Phaseolus vulgaris, acts as an aldose reductase inhibitor (ARI). Soyasaponin Ba activates Akt/GSK3β/β-catenin signaling pathway, reduces lipid accumulation, lowers ROS generation, improves mitochondrial membrane potential, ATP levels, and morphology, and inhibits apoptosis. Soyasaponin Ba can be used for the research of lipid accumulation and secondary diabetic complications .

HY-W337335

1-Palmitoyl-sn-glycerol 3-phosphate sodium salt 1-P-GPA sodium salt	Structural Classification Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Liposome
Palmitoyl-sn-glycerol 3-phosphate (1-P-GPA) sodium salt is a type of phospholipid and a precursor of lipid membranes. 1-Palmitoyl-sn-glycerol 3-phosphate sodium salt can be incorporated into POPC liposomes, resulting in significant changes in membrane curvature. 1-Palmitoyl-sn-glycerol 3-phosphate sodium salt can induce platelet aggregation, but its activity is 30 times lower than that of 1-hexadecyl-sn-glyceryl-3-phosphate .

HY-129459R

α-Tocotrienol (Standard)	Structural Classification Monophenols Phenols Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
α-Tocotrienol (Standard) is the analytical standard of α-Tocotrienol. This product is intended for research and analytical applications. α-Tocotrienol is an isoform of vitamin E and found in vegetables, fruits, seeds, nuts, grains, and oils. Vitamin E plays a role as an antioxidant, in lowering cholesterol and other lipids, as a neuroprotective and anticancer agent, and in cardiovascular disease protection.

HY-126967A

1-Palmitoyl-sn-glycerol 3-phosphate 1-P-GPA	Structural Classification Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Liposome
1-Palmitoyl-sn-glycerol 3-phosphate (1-P-GPA) is a phospholipid and lipid membrane precursor. 1-Palmitoyl-sn-glycerol 3-phosphate integrates into POPC liposomes, causing significant changes in membrane curvature. 1-Palmitoyl-sn-glycerol 3-phosphate induces platelet aggregation, but its activity is 30-fold lower than that of 1-hexadecyl-sn-glyceryl-3-phosphate .

HY-W015924R

2-Hydroxyisobutyric acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
2-Hydroxyisobutyric acid (Standard) is the analytical standard of 2-Hydroxyisobutyric acid. This product is intended for research and analytical applications. 2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].

HY-W144096

Methyl 2,4,6-trihydroxybenzoate	Classification of Application Fields Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Drug Metabolite
Methyl 2,4,6-trihydroxybenzoate is a metabolite of 2,4,6-trihydroxybenzoate and exhibits properties as an antioxidant, lipid lowering and anticancer activities .

HY-W012241R

Dodecanedioic acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Dodecanedioic acid (Standard) is the analytical standard of Dodecanedioic acid (HY-W012241). This product is intended for research and analytical applications. Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-100313

YM-53601 free base	Alkaloids Carbazole Alkaloids	Farnesyl Transferase HCV
YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .

HY-N0224R

Epigoitrin (Standard)	Alkaloids Structural Classification Other Alkaloids Cruciferae Isatis tinctoria L. Plants Source Classification	Influenza Virus Reference Standards
Epigoitrin (Standard) is the analytical standard of Epigoitrin. This product is intended for research and analytical applications. Epigoitrin is a natural alkaloid that provides protection against influenza infection by reducing the host’s susceptibility to influenza virus under stress. Epigoitrin exerts antiviral activity against influenza A1 virus FM1 via inhibiting virus attachment and multiplication in vitro. Epigoitrin also has lipid-lowering effects .

HY-B1028R

Pantethine (Standard) D-Pantethine (Standard); LBF disulfide (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite SARS-CoV
Pantethine (Standard) is the analytical standard of Pantethine. This product is intended for research and analytical applications. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .

HY-N16527

7-O-Galloyl-D-sedoheptulose	Structural Classification Cornaceae Cornus officinalis Sieb. et Zucc. Phenols Polyphenols Plants Source Classification	TNF Receptor Interleukin Related NADPH Oxidase Reactive Oxygen Species (ROS) NF-κB COX NO Synthase JNK AP-1 TGF-β Receptor
7-O-Galloyl-D-sedoheptulose is an orally effective polyphenolic compound. 7-O-Galloyl-D-sedoheptulose lowers the serum levels of glucose, leptin, insulin, C-peptide, resistin, TNF-α, IL-6, and increases the serum level of adiponectin. 7-O-Galloyl-D-sedoheptulose significantly reduces the levels of ROS and lipid peroxidation products (TBARS) by down-regulating the protein expression of NADPH oxidase subunit Nox-4 and p22phox. 7-O-Galloyl-D-sedoheptulose down-regulates NF-κB and related pro-inflammatory factors (COX-2, iNOS), inhibits the phosphorylation of JNK and the activity of its downstream AP-1. 7-O-Galloyl-D-sedoheptulose reduces the expression of TGF-β1 and fibronectin, indicating its potential in anti-tissue fibrosis. 7-O-Galloyl-D-sedoheptulose can be used for the study of type 2 diabetes and its hepatic and pancreatic complications .

HY-W144096R

Methyl 2,4,6-trihydroxybenzoate (Standard)	Phenols Polyphenols Endogenous metabolite Source Classification	Drug Metabolite Reference Standards
Methyl 2,4,6-trihydroxybenzoate is a metabolite of 2,4,6-trihydroxybenzoate and exhibits properties as an antioxidant, lipid lowering and anticancer activities .

HY-N0458R

Pedunculoside (Standard)	Aquifoliaceae Triterpenes Structural Classification Terpenoids Parameria laevigata (Juss.) Moldenke Plants Source Classification	Reference Standards Fatty Acid Synthase (FASN)
Pedunculoside (Standard) is the analytical standard of Pedunculoside. This product is intended for research and analytical applications. Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .

HY-B1189R

Meglutol (Standard) Dicrotalic acid (Standard); 3-Hydroxy-3-methylglutaric acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite Reference Standards
Meglutol (Standard) is the analytical standard of Meglutol. This product is intended for research and analytical applications. Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .

HY-N0309R

Soyasaponin Ba (Standard)	Triterpenes Structural Classification Leguminosae Glycine max (L.) merr Terpenoids Plants Source Classification	Reference Standards Aldose Reductase Akt GSK-3 β-catenin Reactive Oxygen Species (ROS) Mitochondrial Metabolism Apoptosis c-Myc
Soyasaponin Ba (Standard) is the analytical standard of Soyasaponin Ba (HY-N0309). Soyasaponin Ba is a soyasaponin that can be isolated from Phaseolus vulgaris, acts as an aldose reductase inhibitor (ARI). Soyasaponin Ba activates Akt/GSK3β/β-catenin signaling pathway, reduces lipid accumulation, lowers ROS generation, improves mitochondrial membrane potential, ATP levels, and morphology, and inhibits apoptosis. Soyasaponin Ba can be used for the research of lipid accumulation and secondary diabetic complications .

HY-B2171AR

Carubicin hydrochloride (Standard) Carminomycin hydrochloride (Standard); Carminomicin I hydrochloride (Standard)	Quinones Microorganisms Anthraquinones Phenols Polyphenols Source Classification	Reference Standards Apoptosis
Isoflavone (Standard) is the analytical standard of Isoflavone. This product is intended for research and analytical applications. Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases .

HY-N0712R

Typhaneoside (Standard)	Flavonols Structural Classification Flavonoids Typhaceae Typha angustifolia L. Phenols Polyphenols Plants Source Classification	Reference Standards Autophagy
Typhaneoside (Standard) is the analytical standard of Typhaneoside. This product is intended for research and analytical applications. Typhaneoside, extracted from Typha angustifolia L., Typhaneoside can inhibit the excessive autophagy of hypoxia/reoxygenation cells and increase the phosphorylation of Akt and mTOR. Typhaneoside has certain effects on the cardiovascular system, including lowering blood lipid levels, promoting antiatherosclerosis activities, as well as improving immune and coagulation function .

HY-N3031R

Grosvenorine (Standard)	Flavonols Structural Classification Flavonoids Cucurbitaceae Phenols Polyphenols Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang Plants Source Classification	Reference Standards Bacterial Apoptosis Bcl-2 Family MDM-2/p53 Glutathione Peroxidase SOD TNF Receptor Interleukin Related
Grosvenorine (Standard) is the analytical standard of Grosvenorine. This product is intended for research and analytical applications. Grosvenorine is an orally active flavonoid glycoside found in S. grosvenorii. Grosvenorine exhibits antibacterial, antioxidant and antiinflammation activities. Grosvenorine can induce apoptosis and increases anti-apoptotic Bcl-2 protein expression and reduces pro-apoptotic P53 protein expression in gastric tissues. Grosvenorine enhances mucin/glycoprotein secretion, regulates gastric pH, and reduces gastric lesion incidence.Grosvenorine increases glutathione peroxidase, catalase, and SOD levels, reduces lipid peroxidation (MDA), and lowers TNF-α and IL-6 levels. Grosvenorine can be used for the researches of bacterial infection and Gastric ulcer .

HY-N19044

Ilex kudincha extract	Aquifoliaceae Structural Classification Cynanchum wallichii Wight Extract Plants Source Classification	Others
Ilex Kudincha Extracts is derived from the tender leaves of Ilex holly and Ilex kudingcha. Ilex kudincha extract has the effects of lowering blood lipids, increasing myocardial blood supply, and anti-atherosclerosis.

HY-N17745

(-)-EGCG-3'-O-Me	Brassica rapa var. oleifera de Candolle Structural Classification Phenols Polyphenols Plants Brassicaceae Source Classification
(-)-EGCG-3'-O-Me is a catechin derivative (HY-N0898). (-)-EGCG-3'-O-Me inhibits lipid oxidation in rapeseed oil by reducing oxygen consumption and protecting linoleic acid and α-linolenic acid from degradation during heating. The antioxidant activity of (-)-EGCG-3'-O-Me in heated rapeseed oil is lower than that of its non-methylated precursor, (-)-epigallocatechin (EGCG) (HY-N0225) .

HY-N7773

Hibiscetin	Malvaceae Structural Classification Flavonols Flavonoids Hibiscus sabdariffa Linn. Plants Source Classification	TNF Receptor Interleukin Related Caspase SOD
Hibiscetin is an orally active anti-inflammatory, antioxidant, antihyperglycemic, hypolipidemic, hepatoprotective and neuroprotective agent. Hibiscetin reduces the levels of TNF-α, IL-1β and IL-6. Hibiscetin inhibits lipid peroxidation, reduces MDA levels, and induces the activities of antioxidant enzymes CAT, GSH and SOD. Hibiscetin lowers blood glucose, reverses reduced insulin levels, regulates adipokine levels, and reduces elevated AST and ALT levels. Hibiscetin alleviates Rotenone (HY-B1756)-induced akinesia and catalepsy, normalizes neurotransmitter levels, and modulates the activities of activated caspase 3 and BDNF. Hibiscetin can be used in the research of type 2 diabetes, Parkinson's disease and Huntington's disease .

HY-N17773

Hydrangeic acid	Structural Classification Monophenols Hydrangeaceae Phenols Plants Source Classification	PPAR GLUT TNF Receptor
Hydrangeic acid is an orally effective stilbene-type glycolipid metabolism regulator that lowers blood glucose and lipids. It can be isolated from processed leaves of Hydrangea macrophylla var. thunbergii. Hydrangeic acid is associated with glycolipid metabolism and insulin sensitivity regulation. Hydrangeic acid does not directly activate PPARγ or PPARα, but instead upregulates the mRNA expression of adiponectin, PPARγ2, GLUT4, and fatty acid-binding protein aP2, and downregulates TNF-α mRNA expression, promoting adipogenesis, glucose uptake, and GLUT4 translocation in 3T3-L1 cells. Simultaneously, Hydrangeic acid inhibits inflammatory factor-induced NO production, exerting activity in improving insulin resistance. Hydrangeic acid can be used in research related to type 2 diabetes and does not cause liver weight gain as a side effect.

Cat. No.	Product Name	Chemical Structure

HY-114118S3

Semaglutide-13C6,15N TFA

Semaglutide- ¹³C₆, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S1

Semaglutide-d8 tetraTFA

Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8

Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-B0258S

Gemfibrozil-d6
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-W012241S1

Dodecanedioic acid-d4

Dodecanedioic acid-d₄ is the deuterium labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-138166S

Rosuvastatin lactone-d6

Rosuvastatin lactone-d₆ is the deuterium labeled Rosuvastatin lactone. Rosuvastatin lactone is a metabolite of Rosuvastatin (HY-17504A), a statin lipid-lowering agent and HMG-CoA inhibitor. Rosuvastatin lactone exhibits endothelium-independent and HMG-CoA reductase-independent vasorelaxant activity in rat aortic rings, and its vasorelaxant effect is jointly mediated by NO produced by inducible nitric oxide synthase (iNOS) located in vascular smooth muscle and activation of potassium channels. Rosuvastatin lactone itself has no lipid-lowering effect .

HY-W012241S

Dodecanedioic acid-d20

Dodecanedioic acid-d₂₀ is the deuterium labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-W777762

Dodecanedioic Acid-13C12

Dodecanedioic Acid- ¹³C₁2 is the ¹³C-labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-109523S

Cerivastatin-d3 sodium

Cerivastatin-d₃ sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-B1028S

Pantethine-15N2

Pantethine- ¹⁵N₂ is the ¹⁵N₂ labeled Pantethine. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .

HY-B0258S1

Gemfibrozil-d6-1
Gemfibrozil-d6-1 (CI-719-d6-1) is the deuterium labeled Gemfibrozil (HY-B0258). Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively .

HY-B1415S

Clofibric acid-d4

Clofibric acid-d₄ is the deuterium labeled Clofibric acid (HY-B1415). Clofibric acid also is an herbicideClofibric acid (Chlorofibrinic acid) is an orally active PPARα agonist. Clofibric acid inhibits the fimbriation of Escherichia coli. Clofibric acid increases SOD activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research .

Cat. No.	Product Name		Classification

HY-W591424

m-PEG2000-NHS ester mPEG2000-SC; mPEG2000-Succinimidyl ester		Polymers
m-PEG2000-NHS ester (mPEG2000-SC) is a reagent with both cell adhesion inhibition and peptide conjugation functions. The NHS ester group of m-PEG2000-NHS ester forms stable amide bonds with primary amine-containing molecules (e.g., the N-terminus of MMP-2-cleavable octapeptide) to generate mPEG-peptide intermediates for liposome surface modification. When m-PEG2000-NHS ester is immobilized on a cystamine-modified gold surface, it can construct an in vitro model for cell adhesion kinetic studies, and higher PEG density and thicker layers correlate with lower cell adhesion rates. m-PEG2000-NHS ester can synthesize MMP-2-responsive PEGylated lipid conjugates to achieve MMP-triggered dePEGylation in the tumor microenvironment. m-PEG2000-NHS ester can be used in studies related to colon cancer and other conditions .

HY-130345

PAF (C18)		Phospholipids
C18-PAF, octadecane PAF, is the ligand of platelet-activating factor and PAF G protein-coupled receptor (PAFR). C18-PAF has renovasodilator properties and antihypertensive lipid properties. C18-PAF increases renal blood flow and causes dose-dependent systemic hypotension .

HY-W800776

DORI 1,2-Dioleoyl-3-dimethyl-hydroxyethylammonium bromide		Cationic Lipids
DORI is a cationic lipid that can deliver plasmid DNA in vitro. DORI has lower cytotoxicity and high transfection efficiency .

HY-17650

DMDHP (±)-Dimyristoyl-2,3-dimethylhydroxypropylamine		Cationic Lipids
DMDHP ((±)-Dimyristoyl-2,3-dimethylhydroxypropylamine) is a cationic lipid with a polar head group containing a dihydroxy group. DMDHP exhibits superior transfection efficiency and lower toxicity at high DNA doses in mouse intrapulmonary transfection model. DMDHP is commonly used for gene delivery .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

lipid lowering

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products